KARACHI: CanSino Biologics Inc has offered 20 million shots to Pakistan as it gets ready to release efficacy results “in a few days” from phase III trials that have recently been.
Lahore CanSino vaccine trial concludes with no severe reactions reported
Most participants developed antibodies to coronavirus SAMAA | Daniyal Umer - Posted: Jan 23, 2021 | Last Updated: 3 months ago SAMAA | Daniyal Umer Posted: Jan 23, 2021 | Last Updated: 3 months ago
Photo: SAMAA TV screengrab
Listen to the story
The trial of a coronavirus vaccine from China s CanSino Biologics has been successfully completed at Lahoreâs University of Health Sciences. No severe reactions have been reported.
Only 5% of those vaccinated experienced a mild fever after being administered the shots, according to UHS Vice Chancellor Professor Javed Akram.Â
Clinical trials of the same vaccine recorded no severe adverse effects as well, CanSinoâs Chief Scientific Officer Zhu Tao said in September 2020.
Chinese vaccine maker to release efficacy results of phase-III trials undergoing in Pakistan ‘in a few days’
Thousands of Pakistanis have volunteered to take part in the final-stage trial of a Chinese vaccine for Covid-19. PHOTO: AFP/FILE
Chinese pharmaceutical company CanSino Biologics Inc has offered 20 million shots of its Covid-19 vaccine to Pakistan as it gets ready to release efficacy results “in a few days” from phase-III trials that have recently been completed in the country, its local partner told
The Chinese maker of the single-shot vaccine will be giving Pakistan preferential access and pricing, said Hasan Abbas Zaheer, technical adviser at AJM Pharma Pvt.
Chinese Covid-19 vaccine maker CanSino to offer Pakistan 20 million doses
Vials of a Covid-19 vaccine by CanSino Biologics Inc
(REUTERS)Premium
The Chinese maker of the single-shot vaccine will be giving Pakistan preferential access and pricing
The company also plans to decrease the cost of procuring the vaccines by 25%, through filling the vials locally
Share Via
Read Full Story
CanSino Biologics Inc. has offered 20 million shots to Pakistan as it gets ready to release efficacy results “in a few days from phase III trials that have recently been completed in the South Asian nation, according to its local partner.
The Chinese maker of the single-shot vaccine will be giving Pakistan preferential access and pricing, said Hasan Abbas Zaheer, technical adviser at AJM Pharma Pvt., the local partner. It has already applied with Pakistan’s drug regulator to get approval.